Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Harvard Catalyst Profiles is currently experiencing a partial system outage. Login/Edit modules are currently disabled.

Saud H Aldubayan, M.B.,B.S.

Profile Picture

King Khalid University, Saudi ArabiaMD07/2009Clinical Medicine
University of Toronto, Toronto, Canada06/2014Internal Medicine
Harvard Medical School, Boston, MA06/2017Clinical Genetics and Genomics
Harvard Academy for Clinical and Translational Sciences, Boston, MA05/2018Clinical and Translational Sciences
The Broad Institute of MIT and Harvard, Cambridge, MA06/2018Computational Cancer Genomics
2013 - 2013
In-Training Research Award
2015 - 2015
King’s Nonprofit Excellence Award
2017 - 2017
Conquer Cancer Foundation Merit Award
2017 - 2017
Boston Children’s Hospital Alumni Association Award
2018 - 2018
Charles A. King Trust Postdoctoral Fellowship
2018 - 2021
Career Development Award
2018 - 2021
Young Investigator Award

I am dedicated to a career as a physician-scientist in the emerging fields of clinical computational cancer genomics and precision oncology. My research focuses on utilizing various computational approaches to identify novel inherited genomic predictors of cancer risk, response to therapy, and risk of disease progression. As a clinical cancer geneticist and a computational biologist, I use my expertise in clinical genetics, molecular genomics, biostatistics, bioinformatics and computational methods to explore clinically-focused questions using genomic, transcriptomic and methylation data of cancer patients. Towards that end, I built a novel germline computational and pathogenicity enrichment analysis framework that was successfully used to identify novel germline predictors of disease progression and failure of therapy in metastatic prostate cancer patients (Pritchard et al. NEJM 2016), which has since informed the NCCN recommendations for germline genetic testing in this patient population. I have since led the germline genomics program in the Clinical Computational Oncology Laboratory at Dana-Farber Cancer Institute to expand the utility of germline genomic testing in cancer patients by leveraging state-of-the-art computational approaches to study the missing heritability of rare and common cancers. This effort has resulted in identifying two novel colorectal cancer (CRC) predisposition genes (ATM and PALB2), explaining the CRC risk in 1.2% of all unselected and early-onset CRC patients and expanding the diagnostic yield of germline genetic testing by 20% (AlDubayan et al. AJHG 2018). In addition, I led an international team of investigators to identify the first Mendelian germline predisposition gene in testicular germ cell tumors, CHEK2, with potentially immediate clinical and mechanistic implications (AlDubayan et al. JAMA Oncology 2019). Overall, I am a physician-scientist active in clinical and translational computational cancer genomics research through my effort as a clinical cancer geneticist and a computational biologist at Dana-Farber Cancer Institute, Brigham and women's Hospital, Harvard Medical School, and the Broad Institute of MIT and Harvard.

The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. Career Development Award (CDA) (Saud AlDubayan, MD) Jul 1, 2018 - Jun 30, 2021
    American Society of Clinical Oncology (ASCO) (USA)
    Dissecting inherited and acquired genetic mediators of testicular germ cell tumor (TGCT) initiation and progression
    Role: Principal Investigator
  2. Young Investigator Award (YIA) (Saud AlDubayan, MD) Jul 1, 2018 - Jun 30, 2021
    The Prostate Cancer Foundation (PCF) (USA)
    Novel epidemiological and computational genomic approaches to explore the missing heritability of primary and metastatic prostate cancer
    Role: Principal Investigator
  3. Computational Cancer Genomics Fellowship (Saud AlDubayan, MD) Jul 1, 2017 - Dec 31, 2019
    Using multi-generational integration of somatic and germline genomes to identify hereditary risk factors in patients with undiagnosed familial cancer syndromes
    Role: Principal Investigator

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
This operation might take several minutes to complete. Please do not close your browser.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Aldubayan's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (180)
Co-Authors (78)
Similar People (60)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.